EPHA #A2MDialogues The Presidencies’ perspective on the pharmaceutical strategy

(1:3:25)

EPHA #A2MDialogues: Getting it right: Recommendations for a European BARDA

(52:6)

EPHA #A2MDialogues Unleashing meaningful innovation through regulatory reform 19 October 2020

(59:)

EPHA #A2MDialogues Pharma \u0026 COVID19 Winners, losers, prospects 191120

(1:7:59)

EPHA #A2MDialogues: The EU's IP Strategy enabler or barrier 27 October

(1:6:35)

EPHA #A2MDialogues Sustainable access to effective antibiotics what should the EU do

(1:1:1econd)

EPHA #A2MDialogues: Negotiating with pharma: lessons from the EU COVID 19 vaccines negotiations

(1:6:47)

EPHA #A2MDialogues After COVID19 what next for medicines policies

(59:31)

EPHA A2M Dialogues: The Oslo Medicines Initiative - a new social contract with pharma

(1:12)

Setting the Scene | EPHA Access to Medicines Forum 2023 #A2M

(10:38)

Closing Remarks | EPHA Access to Medicines Forum 2023 #A2M

(8:)

Opening Remarks | EPHA Access to Medicines Forum 2023 #A2M

(4:46)

ESIP MEDEV webinar on the EU pharma legislation - Strong evidence for informed and timely decisions

(1:3:8)

HFY Stories: Terran Contact - Chapter 68 | Mamba Team (second half)

(16:55)

Why and how should we prioritize marginalized communities in COVID-19 vaccines rollout in Europe?

(1:2:23)

Commissioner Kyriakides eudebates the NEW Pharmaceutical Strategy for Europe

(7:57)

Innovation in medical technologies - Dr Andrew Elder on investing in medical technologies

(23:1econd)

Can Health Technology Assessment Control Spending And Reward Innovation?

(1:15:51)